602 Results

New analysis shows cardiorenal risk reductions of Jardiance are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria.

 Added 7 days ago

A new post-hoc analysis of data from the EMPA-REG OUTCOME trial indicates a consistent effect of Jardiance (empagliflozin) on reducing...

DECLARE-TIMI 58 phase III trial of Farxiga/Forxiga cut the progression of kidney disease in type 2 diabetes patients.

 Added 8 days ago

The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) phase...

Data from EV 201 trial of enfortumab vedotin for bladder cancer is presented at ASCO.

 Added 15 days ago

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that data from the first cohort of a pivotal phase II clinical...

Phase III TITAN study of Erleada shows improved PFS and OS in prostate cancer.

 Added 17 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings from the investigational Phase III TITAN study, which showed the...

Baxter announces new research on 3-in-1 Oxiris filter Set for continuous renal replacement therapy and sepsis management.

 Added 21 days ago

axter International Inc. announced that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world...

FDA approves Bavencio + Inlyta to treat renal cell carcinoma

 Added 1 month ago

Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) in combination with axitinib for the first-line treatment...

Pooled cardiovascular safety analyses of the global Phase III programme for roxadustat

 Added 1 month ago

AstraZeneca has announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat...

FDA approves Qternmet XR to improve glycaemic control in adults with type-2 diabetes

 Added 1 month ago

The FDA has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to...

Nabriva Therapeutics received a CRL from the FDA for Contepo

 Added 1 month ago

Nabriva Therapeutics plc announced that it received a Complete Response Letter (CRL) from the FDA for the New Drug Application...

Keytruda and Inlyta approved by FDA to treat first line renal cell carcinoma

 Added 1 month ago

Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase...

Load more